Intrapartum Monitoring Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type (Electrodes {Intrauterine Pressure Catheter (IUPC), Transducer for Uterine Contractions, Fetal Scalp Electrodes, Transducer for Fetal Heart Rate}, Monitors), By End User (Hospitals, Maternity Centers, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 1.78 Billion
CAGR (2026-2031)	7.91%
Fastest Growing Segment	Hospitals
Largest Market	North America
Market Size (2031)	USD 2.81 Billion

Market Overview

The Global Intrapartum Monitoring Devices Market is projected to grow from USD 1.78 Billion in 2025 to USD 2.81 Billion by 2031 at a 7.91% CAGR. Intrapartum monitoring devices are diagnostic technologies employed to track fetal heart rate and uterine activity during labor, facilitating the early detection of distress and complications. The market is continually expanding due to the rising incidence of high-risk pregnancies and a growing global focus on reducing maternal and neonatal mortality through real-time surveillance. This growth is further supported by technological advancements in non-invasive monitoring solutions that enhance patient mobility and comfort. According to the March of Dimes, in 2024, nearly 380,000 babies were born preterm in the United States, highlighting the critical demand for effective labor monitoring solutions.

However, the market encounters a significant obstacle in the form of stringent regulatory frameworks which can delay the approval and commercialization of new devices. Additionally, the substantial cost associated with advanced monitoring systems limits their adoption in lower-income healthcare settings, potentially hindering broader market expansion across developing regions.

Key Market Drivers

The rising prevalence of preterm births and high-risk pregnancies serves as a primary catalyst for the Global Intrapartum Monitoring Devices Market, necessitating continuous surveillance to mitigate adverse outcomes. Clinicians increasingly rely on advanced diagnostic tools to manage complex deliveries associated with factors such as advanced maternal age, obesity, and surgical interventions. This trend is evidenced by the escalating rate of operative deliveries, which requires vigilant real-time fetal tracking to ensure safety. According to the Centers for Disease Control and Prevention, July 2025, in the 'Births in the United States, 2024' report, the primary cesarean delivery rate in the country increased to 22.9%, reflecting the growing complexity of labor management. This intense clinical need is further underscored by persistent prematurity statistics that sustain the demand for effective perinatal oversight. According to the March of Dimes, in 2025, the national preterm birth rate in the United States remained at 10.4%, highlighting the critical necessity for robust monitoring solutions in high-risk obstetric settings.

Technological advancements in non-invasive and wireless monitoring systems are further propelling market growth by addressing the limitations of traditional cabled sensors. Innovations in telemetry and signal processing now allow expectant mothers greater freedom of movement during labor, which facilitates physiological progress while maintaining clinical data integrity. These wireless solutions are seeing rapid adoption within hospital networks seeking to modernize their obstetrics departments and improve patient comfort without compromising signal accuracy. For instance, according to Koninklijke Philips N.V., February 2025, in the 'Fourth Quarter and Annual Results 2024', the company's Connected Care business segment, which encompasses patient monitoring solutions, recorded a 7% increase in comparable sales for the fourth quarter. This uptake illustrates the industry-wide shift towards integrated, mobility-enhancing platforms that support both clinical efficiency and an improved birthing experience.

Download Free Sample Report

Key Market Challenges

The substantial cost associated with advanced intrapartum monitoring systems serves as a primary barrier to their widespread adoption, directly impeding the growth of the global market. Healthcare facilities, particularly those in resource-constrained environments, often struggle to allocate sufficient capital for these diagnostic technologies. When hospitals prioritize immediate operational expenditures over capital investments, the procurement of modern monitoring units is frequently postponed. This financial pressure creates a significant bottleneck, as providers are forced to rely on legacy equipment rather than purchasing newer, non-invasive solutions, thereby reducing the overall sales volume for manufacturers.

This pattern of deferred investment is substantiated by recent industry data highlighting the severity of the fiscal challenges faced by providers. According to the American Hospital Association, in 2025, approximately 94% of healthcare administrators expected to delay equipment upgrades to manage growing financial strain. Such a high rate of deferred purchasing indicates that even when improved monitoring capabilities are available, economic limitations effectively prevent their integration into clinical practice. Consequently, the market experiences prolonged sales cycles and reduced penetration rates, as the economic viability of acquiring high-value monitoring devices remains out of reach for a significant portion of the healthcare sector.

Key Market Trends

The deployment of Automated Cardiotocography (CTG) Interpretation Systems is rapidly transforming the market by addressing the critical challenge of inter-observer variability in reading fetal heart rate traces. Healthcare providers are increasingly integrating these algorithmic solutions to standardize clinical decision-making and enhance the safety of high-risk deliveries. Unlike traditional manual interpretation, which is prone to human error and fatigue, these automated systems provide objective, continuous analysis of fetal signals, allowing for earlier intervention in complex cases. This shift towards expanded computational surveillance is evidenced by the industry's push to cover more vulnerable patient cohorts. According to PeriGen, February 2025, in the 'PeriGen's AI-Powered Fetal Monitoring System Receives FDA Clearance' press release, the company’s pattern recognition technology has been cleared to analyze fetal heart rate patterns for fetuses as young as 32 weeks gestation, significantly broadening the safety net for preterm labor management.

Simultaneously, the Integration of Artificial Intelligence for Real-Time Risk Assessment is driving market growth by streamlining clinical workflows and reducing the operational burden on obstetric staff. Beyond simple signal tracking, advanced AI is now embedded directly into diagnostic platforms to automate complex measurements and enhance anatomical visualization during labor and delivery triage. This technological evolution allows clinicians to obtain critical physiological data with greater speed and consistency, which is vital during time-sensitive intrapartum emergencies. The impact of such efficiency-focused innovation is substantial. According to GE HealthCare, January 2025, in the 'GE HealthCare Unveils AI-Enhanced Women's Health Ultrasound System' announcement, the introduction of the SonoPelvicFloor 3.0 feature has demonstrated the ability to reduce pelvic floor measurement exam time by up to 80%, illustrating how AI-driven automation is successfully optimizing the speed and accuracy of obstetric assessments.

Segmental Insights

The Hospitals segment is recognized as the fastest-growing category in the Global Intrapartum Monitoring Devices Market. This expansion is primarily driven by the global shift toward institutional deliveries to ensure immediate access to critical care during labor. The rising prevalence of high-risk pregnancies further necessitates the continuous, specialized surveillance that only hospital infrastructures can provide. Additionally, guidelines from institutions such as the World Health Organization promoting skilled birth attendance have accelerated the adoption of monitoring technologies in these facilities. Consequently, hospitals are increasingly investing in reliable devices to adhere to safety protocols and improve patient outcomes.

Regional Insights

North America maintains a leading position in the global intrapartum monitoring devices market due to extensive healthcare infrastructure and substantial healthcare spending. The region benefits from established regulatory frameworks by the U.S. Food and Drug Administration, which facilitate the timely approval and commercialization of new medical technologies. Furthermore, the rising incidence of preterm births and pregnancy complications drives consistent clinical demand for effective fetal and maternal monitoring solutions. The presence of major device manufacturers within the United States also ensures high product accessibility and widespread adoption across hospitals and clinics throughout the region.

Recent Developments

• In October 2025, Huntleigh Healthcare received FDA 510(k) clearance for its Sonicaid Team3 and OBIX BeCA triplet fetal monitors, addressing the complex needs of multi-fetal pregnancy management. This regulatory milestone introduced a purpose-built solution for monitoring high-risk triplet gestations to the United States market. The system was designed to provide uncompromised signal quality and intuitive workflows, enabling clinicians to track three fetal heart rates simultaneously with greater confidence. The monitors were distributed in hospital settings through a partnership with Clinical Computer Systems Inc., enhancing the technological capabilities available for labor and delivery units handling complicated multiple births.
• In February 2025, PeriGen secured FDA clearance for Patterns 3.0, an updated version of its artificial intelligence-powered fetal monitoring software. This regulatory approval expanded the system's indication to include the analysis of fetal heart rate patterns for pregnancies starting at 32 weeks of gestation, down from the previous limit of 36 weeks. The software utilized proprietary pattern recognition technology to detect, label, and measure features such as accelerations, decelerations, and baseline variability in electronic fetal monitoring records. This enhancement aimed to support clinicians in managing preterm high-risk pregnancies by providing automated, objective interpretation of critical intrapartum data.
• In February 2024, GE HealthCare obtained FDA 510(k) clearance for its Novii+ Wireless Patch Solution, an advanced maternal and fetal monitoring platform. This cleared indication expanded the device's use to pregnant patients at or beyond 34 weeks of gestation, improving its utility for high-risk cases compared to previous versions. The system featured a belt-free, wearable sensor that non-invasively measured and displayed fetal heart rate, maternal heart rate, and uterine activity. By enabling wireless monitoring, the solution offered patients greater mobility during labor while providing care teams with continuous, real-time data to assess fetal well-being and intervene when necessary.
• In January 2024, Bloomlife received clearance from the U.S. Food and Drug Administration for its MFM-Pro device, marking a significant transition from consumer-focused technology to the medical market. This prescription-based wearable solution was designed to monitor both maternal and fetal heart rates in clinical and home settings. The device utilized advanced cloud-based processing to non-invasively measure the body's electrical activity and algorithmically extract vital heart rate data. This regulatory milestone allowed the company to provide healthcare providers with a remote monitoring tool intended to support the management of high-risk pregnancies through accessible, medical-grade physiological data.

Key Market Players

• Cardinal Health Inc.
• GE Healthcare Technologies Inc.
• Koninklijke Philips N.V.
• MindChild Medical Inc.
• The Cooper Companies, Inc.
• General Electric Company
• Huntleigh Healthcare Limited
• MedGyn products, Inc.
• Rocket Medical plc
• Stalwart Meditech Pvt Ltd.

By Product Type	By End User	By Region
Electrodes {Intrauterine Pressure Catheter (IUPC) Transducer for Uterine Contractions Fetal Scalp Electrodes Transducer for Fetal Heart Rate} Monitors	Hospitals Maternity Centers Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Intrapartum Monitoring Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Intrapartum Monitoring Devices Market, By Product Type:

• Electrodes {Intrauterine Pressure Catheter (IUPC)
• Transducer for Uterine Contractions
• Fetal Scalp Electrodes
• Transducer for Fetal Heart Rate}
• Monitors

• Intrapartum Monitoring Devices Market, By End User:

• Hospitals
• Maternity Centers
• Others

• Intrapartum Monitoring Devices Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE